Tag: neurodegenerative diseases
Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical ... Read More
Alpha Cognition advances Alzheimer’s treatment with new patent filing
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a pioneering biopharmaceutical company in the development of novel treatments for neurodegenerative diseases, has recently taken a significant ... Read More
Olatec Therapeutics set to launch dapansutrile Phase 2 trial in Parkinson’s disease
Olatec Therapeutics, Inc. (Olatec), a leader in the field of selective NLRP3 inhibitors, has embarked on a journey to tackle Parkinson's disease, a neurodegenerative disorder ... Read More
Hemogenyx Pharmaceuticals innovates brain cancer treatment with CBR delivery
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant advancement in medical science by demonstrating the ability to deliver its proprietary ... Read More
Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1
Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA's approval to commence Phase II clinical study of its NLRP3 inhibitor, ZYIL1, ... Read More
Merck to acquire Caraway Therapeutics in $610m deal for neurodegenerative disease treatments
Merck and Caraway Therapeutics, Inc. have announced a definitive agreement in which Merck, through a subsidiary, will acquire Caraway Therapeutics. The total potential consideration for ... Read More
Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS
RELYVRIO FDA approval for ALS : Amylyx Pharmaceuticals has secured approval for RELYVRIO (sodium phenylbutyrate and taurursodiol) from the US Food and Drug Administration (FDA) ... Read More
Arkuda Therapeutics gets $64m booster to advance neurodegenerative treatment
Arkuda Therapeutics, a US-based biotechnology company, has raised $64 million in Series B financing. The new funding will help Arkuda Therapeutics boost the production of ... Read More
Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal
Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in ... Read More
Clene Nanomedicine raises $42.5m for developing nanocatalysts for neurodegenerative diseases
Clene Nanomedicine, which is engaged in developing nanocatalysts for the treatment of bioenergetic failure associated with neurodegenerative diseases, has raised $42.5 million in a Series ... Read More